Harsh Vardhan bats for total ban on tobacco, its products | WeForNews | Latest News, Blogs Harsh Vardhan bats for total ban on tobacco, its products – WeForNews | Latest News, Blogs
Connect with us

Health

Harsh Vardhan bats for total ban on tobacco, its products

This year’s World No Tobacco Day campaign focuses on protecting children and young people from exploitation by the tobacco and related industry.

Published

on

Harsh Vardhan

New Delhi, May 31 : Union Health Minister Harsh Vardhan on the World Tobacco Day on Sunday said the battle against tobacco was a personal fight for him and he wanted total ban on it and its products.

“The battle against tobacco is a personal fight for me. As an ENT surgeon, I’ve been first-hand witness to how it destroys not just the user, but the entire family. I am a votary for a complete ban on tobacco and its products on the World No Tobacco Day to nip the evil in the bud,” he tweeted.

According to the World Health Organisation, every year the tobacco industry spends over $9 billion to advertise its products. Increasingly, it’s targeting youth with nicotine and tobacco products to replace the 8 million people that its products kill every year.

This year’s World No Tobacco Day campaign focuses on protecting children and young people from exploitation by the tobacco and related industry.

The WHO said even during the global pandemic, the tobacco and nicotine industry persisted by pushing products that limited people’s ability to fight coronavirus and recover from the disease.

The industry offered free branded masks and doorstep delivery during quarantine and lobbied for their products to be listed as ‘essential’. Over 40 million young people, aged 13-15 years, had started to use tobacco, it added.

Health

Researchers design reusable silicone rubber face mask with N95 filter

“We also wanted to maximise the reusability of the system, and we wanted systems that could be sterilized in many different ways,” Traverso added.

Published

on

N-95 mask

New York, July 11 : In fight against novel coronavirus, the researchers have developed a reusable silicone rubber face mask with an N95 filter, which they believe could stop viral particles.

According to the study, published in the British Medical Journal Open, the new masks were designed to be easily sterilized and used many times.

The new mask is made of durable silicone rubber and can be manufactured using injection moulding, which is widely used in factories around the world. It requires much less N95 material than a traditional N95 mask.

“One of the key things we recognized early on was that in order to help meet the demand, we needed to really restrict ourselves to methods that could scale,” said study researcher Giovanni Traverso from Massachusetts Institute of Technology (MIT) in the US.

“We also wanted to maximise the reusability of the system, and we wanted systems that could be sterilized in many different ways,” Traverso added.

The researchers decide on silicone rubber — the material that goes into silicone baking sheets, among other products — because it is so durable.

Liquid silicone rubber can be easily moulded into any shape using injection moulding, a highly automated process that generates products rapidly. The masks are based on the shape of the 3M 1860 style of N95 masks, the type normally used at Brigham and Women”s Hospital.

The researchers tested several different sterilization methods on the silicone masks, including running them through an autoclave (steam sterilizer), putting them in an oven, and soaking them in bleach and in isopropyl alcohol.

They found that after sterilization, the silicone material was undamaged.To test the comfort and fit of the masks, the researchers recruited about 20 health care workers from the emergency department and an oncology clinic at Brigham and Women”s Hospital.

All 20 participants passed the fit test, and they reported that they were able to successfully insert and remove the N95 filter. When asked their preference between the new mask, a typical N95 mask, and a standard surgical mask, most either said they had no preference or preferred the new silicone mask, the researchers said.

They also gave the new mask high ratings for fit and breathability.The researchers are now working on a second version of the mask, which they hope to make more comfortable and durable. They also plan to do additional lab tests measuring the masks” ability to filter viral particles.

Continue Reading

Disaster

Remdesivir linked to reduced death risk in severe Covid-19 patients

The mortality rate for patients treated with remdesivir in the analysis was 7.6 per cent at Day 14 compared with 12.5 per cent among patients not taking remdesivir.

Published

on

remdesivir antiviral drug

New York, July 11 : New data revealed by Gilead Sciences has shown that its antiviral drug remdesivir reduces death risk of severe Covid-19 patients by as much as 62 per cent when compared with standard care alone.

This is an important finding that requires confirmation in prospective clinical trials, Gilead said on Friday about the results presented at the virtual COVID-19 conference as part of the 23rd International AIDS Conference.

The analysis included 312 patients treated in the Phase-3 SIMPLE-Severe study and a separate real-world retrospective cohort of 818 patients with similar baseline characteristics and disease severity who received standard of care treatment in the same time period as the SIMPLE-Severe study.

Patients were primarily located in North America (92 per cent, remdesivir cohort vs. 91 per cent, standard-of-care cohort), Europe (5 per cent vs. 7 per cent) and Asia (3 per cent vs. 2 per cent).

The analysis demonstrated that remdesivir treatment was associated with significantly improved clinical recovery and a 62 percent reduction in the risk of mortality compared to standard of care.

Findings from the comparative analysis showed that 74.4 per cent of remdesivir-treated patients recovered by Day 14 versus 59 per cent of patients receiving standard of care.

The mortality rate for patients treated with remdesivir in the analysis was 7.6 per cent at Day 14 compared with 12.5 per cent among patients not taking remdesivir.

“This comparative analysis provides valuable additional information regarding the benefit of remdesivir compared with standard of care alone,” Susan Olender of Columbia University Irving Medical Center said in a statement.

“While not as vigorous as a randomized controlled trial, this analysis importantly draws from a real-world setting and serves as an important adjunct to clinical trial data, adding to our collective understanding of this virus and reflecting the extraordinary pace of the ongoing pandemic.”

The results of this comparative analysis add to the previously presented National Institute of Allergy and Infectious Disease (NIAID) randomized, double-blind, placebo-controlled study in hospitalized patients with COVID-19, which showed that remdesivir shortened time to recovery by an average of four days as compared to placebo — 11 vs. 15 days.

In the NIAID study, patients taking remdesivir trended toward lower mortality compared with those in the placebo group, but this result did not reach statistical significance –7.1 percent vs. 11.9 per cent.

Due to the current public health emergency, the US Food and Drug Administration (FDA) has issued an Emergency Use Authorization for remdesivir for the treatment of hospitalised patients with severe Covid-19.

“These data presented at the Virtual COVID-19 Conference shed additional light on the use of remdesivir in specific patient populations, including those that may be susceptible to higher rates of COVID-19 infection, as well as others that are particularly vulnerable, including children and pregnant and postpartum women,” said Merdad Parsey, MD, PhD, Chief Medical Officer, Gilead Sciences.

Continue Reading

Health

PM Modi directs for real-time monitoring of COVID-19 situation

The review meeting was attended by Union Home Minister Amit Shah, Union Health Minister Harsh Vardhan, Cabinet Secretary Rajiv Gauba and other senior officials.

Published

on

PM Modi in All Party Meeting

New Delhi, July 11 : Prime Minister Narendra Modi on Saturday directed for real- time monitoring of novel coronavirus pandemic at the national level, stressing on guidance to all affected states that have a high test-positivity rate.

The Prime Minister gave the direction during a COVID-19 review meeting he chaired to take stock of the coronavirus situation across the country and the preparedness of different states.

The meeting comes at a time when India recorded its highest single-day spike of 27,114 new coronavirus cases on Saturday and 519 deaths in the last 24 hours. A total of 8,20,916 corona patients have been reported so far in the country, as per the latest Ministry of Health and Family Welfare data. Of these, 5,15,385 patients have recovered while 2,83,407 active cases remain. In all, 22,123 deaths have been reported till now.

Appreciating the concerted efforts of the Centre, state and local authorities in containing the pandemic in Delhi, Modi directed that a similar approach be adopted in cooperation with other state governments in containing the pandemic in the National Capital Region (NCR) area.

The Prime Minister also reiterated the need to observe personal hygiene and social discipline in public places. He advised for widespread awareness on Covid-19 and asked authorities to lay continuous emphasis on preventing the spread of the infections.

“There is no room for any complacency in this regard,” the Prime Minister said.

The successful example of surveillance and home-based care through ”Dhanvantri Rath” in Ahmedabad was highlighted in the meeting and its emulation in other places stressed.

The review meeting was attended by Union Home Minister Amit Shah, Union Health Minister Harsh Vardhan, Cabinet Secretary Rajiv Gauba and other senior officials.

The Prime Minister specifically focussed on worst-hit states like Maharashtra, which tops the coronavirus infections” chart with 2,38,461 cases and 9,893 casualties so far. Tamil Nadu remained the second worst-hit with 1,30,261 cases, including 1,829 deaths. With 2,089 new coronavirus cases and 42 deaths in the last 24 hours, the national capital”s total reached 1,09,140 and 3,300 deaths.

States with more than 10,000 cases include Gujarat with 40,069 cases and 2,022 deaths, Uttar Pradesh (33,700), Rajasthan (23,174), Madhya Pradesh (16,657), West Bengal (27,109), Haryana (19,934), Karnataka (33,418), Andhra Pradesh (25,422), Telangana (32,224), Assam (14,600) and Bihar (14,575) cases.

Continue Reading
Advertisement

Most Popular